HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.

Abstract
To examine the efficacy of cholinergic enhancement in senile dementia of the Alzheimer type (SDAT), oral physostigmine was given to eight patients in a cross-over trial of three dose levels and a matching placebo. A dose-related improvement in memory as measured by objective verbal memory tests was observed. Performance was significantly better on the highest dose, 2 mg every 2 h, than on the lower doses. The effect was most systematically present for very short-term memory, which raises the question of whether the improvement may involve attention rather than longer term storage and retrieval.
AuthorsS A Beller, J E Overall, A C Swann
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 87 Issue 2 Pg. 147-51 ( 1985) ISSN: 0033-3158 [Print] Germany
PMID3931138 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Physostigmine
Topics
  • Administration, Oral
  • Aged
  • Alzheimer Disease (drug therapy)
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Memory (drug effects)
  • Memory, Short-Term (drug effects)
  • Middle Aged
  • Physostigmine (administration & dosage, adverse effects, therapeutic use)
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: